In the light of the enormous challenges imposed by the EU's eastern enlargement, this paper examines, using pharmaceutical regulation as a case study, how the European Commission attempts to keep the candidate countries' demand for derogations from the acquis communautaire to a minimum, without deviating from the principle that future members have to accept all EU rules. I argue that a dual strategy of both institutionalising the process of regulatory adaptation and decentralising governance renders the enlargement process "smoother", thus reducing the risk of conflicts during pre-accession phase. By establishing a more decentralised and institutionalised mechanism Europeanisation, in which an agency (EMEA) is core actor pan-European forum (PERF) serves as main arena negotiation, European Commission has shown flexibility with regard to method it prepares candidates for implementation acquis. This new strategy "mutual understanding "learning" facilitated efficient adoption EU regulations complex highly standardised sector such pharmaceutical regulation. Expecting that future enlargements will even be sophisticated, solutions support efficiency conflict resolution phase are worth being considered.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Paper provided by School of Politics, International Studies and Philosophy, Queen's University of Belfast in its series Queen's Papers on Europeanisation with number
p0030.